Akèy › Maladi selil fòs › Alabama › Birmingham
Etid klinik pou Maladi selil fòs nan Birmingham, AL
14 etid pou Maladi selil fòs ap chèche patisipan nan sit nan ak bò kote Birmingham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Ap rekriteFaz 3
- University Of Alabama, Birmingham
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
Ap rekriteFaz 1
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Ap rekriteFaz 3
- Uni of Alabama at Birmingham, Birmingham
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Ap rekriteFaz 1/2Volontè an sante akeyi
- University of Alabama Birmingham, Birmingham
SCD Stem Cell Mobilization and Apheresis Using Motixafortide
Ap rekriteFaz 1
- University of Alabama at Birmingham, Birmingham
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Ap rekriteFaz 1/2Volontè an sante akeyi
- University of Alabama at Birmingham, Birmingham
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Ap rekriteFaz 3
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
Early Life Exposures Among Children With Sickle Cell Disease
Ap rekrite
- University of Alabama at Birmingham, Birmingham
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Ap rekriteFaz 4
- University Of Alabama, Birmingham
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
Ap rekriteEtid obsèvasyon
- Children's of Alabama (MRD-HCT), Birmingham
- Children's of Alabama (NT-DMT), Birmingham
Cognitive Remediation Intervention to Prepare for Transition of Care
Ap rekriteFaz 2
- University of Alabama at Birmingham, Birmingham
A Long-term Follow-up Study in Patients Who Received BEAM-101
Ap rekriteEtid obsèvasyon
- University of Alabama at Birmingham, Birmingham
HPC Offered for PRESERVE Expansion
Ap rekriteEtid obsèvasyon
- University of Alabama, Birmingham, Birmingham
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
Ap rekriteEtid obsèvasyon
- University of Alabama, Birmingham (UAB), Birmingham
Etid Maladi selil fòs nan lòt vil
- Atlanta, GA22 etid
- Washington, DC20 etid
- Memphis, TN18 etid
- Chicago, IL18 etid
- Philadelphia, PA15 etid
- New York City, NY13 etid
- St. Louis, MO12 etid
- Durham, NC10 etid
- Cincinnati, OH10 etid
- Houston, TX10 etid
- Boston, MA10 etid
- Pittsburgh, PA9 etid
Lòt etid nan Birmingham
- Kansè (tout kalite)30 etid
- Kansè nan tete24 etid
- Obèsite23 etid
- Kansè ovè23 etid
- Kansè Poumon ki pa ti selil22 etid
- Leksemi mieloïd egi21 etid
- Myelom Miltip18 etid
- BPCO17 etid
- Maladi kadyovaskilè17 etid
- Sipwa16 etid
- Kansè Endomèt16 etid
- Dyabèt Tip 216 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.